ClinicalTrials.gg
RecruitingNCT07487155JUSTICE-TDAHUpdated Aug 11, 2026

Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder

An interventional study of Workshop in Attention Deficit Disorder With Hyperactivity (ADHD) and Substance Use Disorder (SUD), sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by University Hospital, Brest · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France — 20 open to participants now, 20 under way, 2 of them phase 3. Attention Deficit Disorder with Hyperactivity · France.

Planned enrollment
47th of 60
39 · median 80
Started
2026
with 4 others
No phase
42 of 82
12 open now
Primary completion
2028-01
later than 11 of 19 live
Registered
81st of 82
by date

Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, this one is the 47th largest by planned enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2026, is one of 42 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 81st registered.

Attention Deficit Disorder with Hyperactivity

1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

20 of the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, or all of them as a file.
02

Study summary

Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.

03

Conditions studied

  • Attention Deficit Disorder With Hyperactivity (ADHD)
  • Substance Use Disorder (SUD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult, under the supervision of the justice system or monitored by a correctional facility
  • Diagnosis of Substance Use Disorder (SUD)
  • Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
  • No objection from the patient
  • Affiliated with a Social Security system

Exclusion criteria

Exclusion Criteria:

  • Severe or decompensated psychiatric disorders
  • Severe cognitive impairment
  • Lack of understanding of the French language
  • Refusal to participate
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Workshops

    Workshops with a small group of patients.

    Other: Workshop

Interventions

  • OtherWorkshop

    Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study

06

What researchers measure

Primary outcomes

  1. 80% of patients participated in the workshops

    The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through: * Semi-structured pre- and post-intervention interviews * A Likert scale * Workshop participation rate (at least 80%)

    Time frame: From enrollment to the end of wordshop at 6 months

Secondary outcomes

  1. SF-12 quality of life

    The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.

    Time frame: From enrollment to the end of wordshop at 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

Time frame: Data will be available after the publication of result and ending fifteen years following the last visit of the last patient.

Access criteria: Data access requests will be reviewed by the internal committee of BrestUH. Requestors will be required to sign and complete a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 23, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07487155
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Aug 3, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Marie BARAIS, MD
Contact
marie.barais@gmail.com
+332 98 01 64 02
Morgane GUILLOU-LANDREAT, MD
principal investigator · CHU Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion